Panitumumab biosimilar?

Panitumumab is an anti‑EGFR monoclonal antibody used for certain metastatic colorectal cancers (mCRC), typically KRAS/NRAS wild‑type and often in combination with chemotherapy depending on regimen/setting.

A “panitumumab biosimilar” means a highly similar version of the approved panitumumab reference product, made by a different manufacturer, with evidence showing no clinically meaningful differences in quality, safety, and effectiveness.

Key points to know

• Mechanism: Anti‑EGFR (binds the EGFR receptor → inhibits signaling that drives tumor growth).
• Main use: Metastatic colorectal cancer (commonly KRAS/NRAS wild‑type), usually after prior therapy in many jurisdictions; specific line/regimen depends on country and guideline.
• Naming: Biosimilars often have distinct brand names but the same general mechanism and “panitumumab” INN.
• Switching/substitution: In practice, switching between biosimilar and originator is usually considered reasonable when allowed by local policy, but clinicians may specify product continuity.

Commonly approved panitumumab biosimilars (examples)

Biosimilar names vary by country. Some markets have used products such as:

• SB2 / Bemarituzumab? (Not relevant—wrong drug; disregard)
• Onivyde? (wrong) If you tell me your country/region or the brand name you’re seeing, I can confirm which specific panitumumab biosimilar it is and what it’s approved for there.

What I can do next

Reply with one of the following and I’ll tailor the answer:

1. Country (e.g., US, EU, India, Saudi Arabia, etc.)
2. The brand name on the box/prescription
3. Your clinical context (e.g., mCRC KRAS/NRAS status, treatment line)

Then I can provide: approved indication(s), dosing/regimen norms, equivalence notes, and safety considerations.